• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

    358.71 +4.23 (+1.19%)
    Streaming Delayed Price Updated: 9:34 AM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,502
    Open 355.95
    Bid (Size) 354.49 (40)
    Ask (Size) 358.23 (40)
    Prev. Close 354.48
    Today's Range 355.10 - 358.71
    52wk Range 196.45 - 385.22
    Shares Outstanding 1,211,067,023
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    BeOne Medicines to Present at Upcoming Investor Conferences
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    Prediction: These 3 Stocks Will Crush the Market in 2026 ↗
    These stocks all have catalysts on the way that could provide great news for investors. 
    Via The Motley Fool
    Topics Artificial Intelligence

    Performance

    YTD
    +15.3%
    +15.3%
    1 Month
    +7.3%
    +7.3%
    3 Month
    +2.7%
    +2.7%
    6 Month
    +14.2%
    +14.2%
    1 Year
    +51.6%
    +51.6%

    More News

    Read More
    News headline image
    BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    3 Stocks to Buy in February ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features ↗
    Via Benzinga
    News headline image
    Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
    Via Investor's Business Daily
    Topics Economy Government
    News headline image
    U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗
    Via Benzinga
    News headline image
    Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines to Present at Upcoming Investor Conferences
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    What's Going On With Summit Therapeutics Stock On Monday? ↗
    Via Benzinga
    News headline image
    BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
    From BeOne Medicines Ltd.
    Via Business Wire
    News headline image
    BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
    From BeOne Medicines Ltd.
    Via Business Wire

    Frequently Asked Questions

    Is BeOne Medicines Ltd. - American Depositary Shares publicly traded?
    Yes, BeOne Medicines Ltd. - American Depositary Shares is publicly traded.
    What exchange does BeOne Medicines Ltd. - American Depositary Shares trade on?
    BeOne Medicines Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for BeOne Medicines Ltd. - American Depositary Shares?
    The ticker symbol for BeOne Medicines Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market
    What is the current price of BeOne Medicines Ltd. - American Depositary Shares?
    The current price of BeOne Medicines Ltd. - American Depositary Shares is 358.71
    When was BeOne Medicines Ltd. - American Depositary Shares last traded?
    The last trade of BeOne Medicines Ltd. - American Depositary Shares was at 02/20/26 09:34 AM ET
    What is the market capitalization of BeOne Medicines Ltd. - American Depositary Shares?
    The market capitalization of BeOne Medicines Ltd. - American Depositary Shares is 434.42B
    How many shares of BeOne Medicines Ltd. - American Depositary Shares are outstanding?
    BeOne Medicines Ltd. - American Depositary Shares has 434B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.